Delivery Order SPE2DB22D1002-SPE2DB25FLHL4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Jatenzo 237 mg capsules (120 count), with a ceiling value of $2,479.28. This competitive delivery order, issued with firm fixed pricing, represents a non-set-aside award and is scheduled for ultimate completion by August 14, 2025. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,226.39. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this competitive award. The product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Jatenzo 198 mg capsules (120 count). This is a firm fixed-price delivery order with a ceiling value of $1,292.51 and an ultimate completion date of July 31, 2025. The contract is not set aside and represents a competitive award to the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.67 to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120-count units) under a firm fixed-price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025. This is a non-set-aside contract, reflecting competitive procurement practices. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,131.88 to AmerisourceBergen Drug Corp for JATENZO 198 MG Capsule 120S pharmaceutical product, with completion scheduled for August 21, 2025. This firm fixed-price delivery order, awarded on August 20, 2025, represents a non-set-aside competitive award and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Jatenzo 198 mg capsules (120 count) valued at $1,798.32 under a firm fixed price contract type. The order was competitively awarded with no set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery from its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $3,347.66 for Jatenzo 198 mg capsules (120-count units) with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is listed as Conshohocken,...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLHL4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a firm fixed price ceiling value of $1,483.15. This competitively awarded, non-set-aside delivery order is set for completion by September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply chain requirements. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's substantial IDC with DLA demonstrates its capability to fulfill federal medical procurement requirements and support healthcare programs across the Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/9/25 |